The average one-year price target for Super League Enterprise (NasdaqCM:SLE) has been revised to $53.04 / share. This is an increase of 420.00% from the prior estimate of $10.20 dated January 11, 2026 ...

AstraZeneca has already provided the requested information to the FDA and a decision on the updated BLA is expected in the first half of 2026.

Data suggest incidence and prevalence of systemic lupus erythematosus (SLE) vary widely among regions, although the authors noted some regions have been studied more extensively than others. A new ...

A first clinical study suggests allogeneic CD19-targeted CAR-T cell therapy can safely induce durable remission in patients with severe, treatment-refractory systemic lupus erythematosus.

Systemic lupus erythematosus is associated with an increased risk for 16 cancers, including Hodgkin’s and non-Hodgkin’s lymphoma, leukemia and multiple myeloma, but a decreased risk for prostate ...

) has been revised to $10.20 / share. This is a decrease of 14.29% from the prior estimate of $11.90 dated December 18, 2025. The price target is an average of many targets provided by analysts. The ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Colombia and Brazil had the highest prevalence and incidence of systemic lupus erythematosus (SLE), a new investigation found. A new analysis of low- and middle-income countries suggests that cases of ...

When choosing my home for the next four years, it was Stanford’s distinct — but largely under-advertised — residential program that tipped the scale for me. Like most international Indian applicants, ...